Developmentally regulated expression of metastasis-associated antigens in the rat.
The specificity of monoclonal antibodies (mABs) obtained after immunization with a metastasizing rat tumor line was evaluated by screening expression in a variety of nonmetastasizing and metastasizing rat tumor lines. mABs, which by immunohistology and Western blotting recognized metastasizing lines, were used to define the physiological expression of the corresponding antigens during ontogeny as well as in adult rats. From a panel of 12 mABs, 2 recognized structures on metastasizing and nonmetastasizing tumor lines, while 10 stained exclusively metastasizing lines. Five of the latter bound to tumor lines metastasizing either hematogenously or via the lymphatic system. All five recognized an epitope on CD44 variant exon v6. The five remaining mABs, recognizing four independent antigenic entities, only stained tumor lines metastasizing via the lymphatics. Surprisingly, these antigens were also detected in normal tissues: three on epithelial cells either widespread or of the upper gastrointestinal tract or the urogenital system, the fourth preferentially on epithelial cells, but also on nerves and hematopoietic precursor cells, and the fifth on many tissues and cells with a predominance of mesenchyme-derived structures. Notably, during ontogeny, expression on these five antigens was induced in different compartments of the developing fetal and/or maternal part of the placenta. The five newly described metastasis-associated antigens share with CD44v the absence of expression on nonmetastasizing tumor lines as well as expression on distinct, nontransformed cells and induction of expression during ontogeny. Thus, tumor progression may rather be initiated by inappropriate expression or up-regulation of genes, which do not display transforming features, than by de novo appearance of "metastasis genes." Accordingly, metastasizing tumor lines may be a valuable tool to identify developmentally regulated gene products.
Claas
C
C
Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg, Germany.
Herrmann
K
K
Matzku
S
S
Möller
P
P
Zöller
M
M
D000818:Animals; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D014408:Biomarkers, Tumor; D015153:Blotting, Western; D004848:Epithelium / Q000737:chemistry; D018507:Gene Expression Regulation, Developmental / Q000502:physiology; D018960:Hyaluronan Receptors / Q000235:genetics* / Q000276:immunology; D007150:Immunohistochemistry; D008648:Mesoderm / Q000737:chemistry; D008970:Molecular Weight; D009362:Neoplasm Metastasis / Q000235:genetics / Q000276:immunology* / Q000503:physiopathology; D051381:Rats; D011919:Rats, Inbred Strains
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D014408:Biomarkers, Tumor; D018960:Hyaluronan Receptors